Our Mission
Redefine what is preventable and treatable by breaking immune tolerance to tackle diseases that were previously considered incurable or unpreventable.
ADVANCING HEALTHCARE
WITH LENTIVIRAL VECTORS
Lentiviral vectors have the power to cure and prevent major infectious diseases and cancers; revolutionizing global healthcare and the immunotherapy sector.
Our preclinical and proof-of-concept studies have shown very promising results for preventive and therapeutic vaccines based on our technology platform.
We have built a highly synergistic portfolio comprising 19 product candidates at various stages of development, all derived from our proprietary platform.
To support the development of our proprietary lentiviral vector platform, we actively collaborate with academic and industrial partners in Europe, North America and China.
CLINICAL DEVELOPMENT
Given the exceptional quality of our preclinical results, we aim to revolutionize immunotherapy and demonstrate the efficacy of our technology platform through clinical trials, either directly or via collaboration.
In this context, our therapeutic vaccine for HPV-induced cancers is currently being evaluated in a Phase IIa dose-escalation clinical trial conducted in the United States.
In March 2026, our collaborator Jinwei obtained the first IND approval from the Center for Drug Evaluation of the National Medical Products Administration in China, enabling further clinical development.
Through our lentiviral technology that has numerous applications, we can become the leading developer of therapeutic and prophylactic vaccination.
